Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

Peramivir was generally safe and well-tolerated at these dose levels.

Detailed results will be submitted to an upcoming medical meeting.

-- BioCryst reported top-line results from the completed Phase 2a trial of

BCX-4208 in subjects with moderate to severe plaque psoriasis were

consistent with interim findings. BCX-4208, a potent, rationally

designed, orally available purine nucleoside phosphorylase inhibitor,

met its primary endpoint of safety and tolerability and displayed

dose-dependant reductions in peripheral blood lymphocyte counts. The

pharmacokinetic and pharmacodynamic results suggest that BCX-4208 may

have utility in diseases dependant on T-cells, B-cells or uric acid.

The Phase 2a results have been accepted for presentation at the 50th

American Society of Hematology Annual Meeting and Exposition (ASH),

which will be held in San Francisco, December 6-9, 2008.

-- The forodesine HCl pivotal trial in cutaneous T-cell lymphoma (CTCL)

continues to enroll subjects with CTCL stages IIB through IVA who have

failed three systemic therapies. The multinational study is evaluating

once daily oral forodesine HCL treatment and is being conducted in

accordance with a Special Protocol Assessment agreement between the U.S.

Food and Drug Administration and BioCryst. A laboratory study of

forodesine HCl in leukemia cells has been accepted for presentation at

ASH.

Conference Call and Web cast

BioCryst's management team will host a conference call and Web cast on Friday, October 31, 2008, at 8:30 a.m. Eastern Time to discuss the financial results and recent developments within the Company's programs. To participate in the conference call, please dial 1-800-860-2442 (United States) or 1-412-858-4600 (International). No passcode is needed for the call. The Web ca
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 AudioNotch is ... new therapy for the treatment of tinnitus. Patients listen ... frequency, and over a period of weeks to months, their ... Therapy in two forms: Notched Music and Notched White Noise. ...
(Date:1/14/2014)... 14, 2014  3D Communications, a leading provider of strategic communications services ... media events in the United States and ... Virginia Cox , JD, is returning to the firm,s ... re-joins 3D after more than two years of service as Associate ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Former FDA Associate Commissioner Returns To 3D Communications 2
... Ion Trap MS n , , , ... Shaler, , Paul Shieh, and William S. Hancock, , , ... Protein Glycosylation , , , , The ... mass spectrometer with MS n , capability., , , ...
... , , , , , Andreas ... , , , , ... Thermo Finnigan LCQTMion , trap mass spectrometer with MS n capability. ... , Calmodulin (CaM) is the primary high-affinity Ca ...
... , , , , , ... in eukaryotic cell cultures , requires double-stranded molecules known ... licensed supplier of siRNA, offering a custom , ... directed against common target genes, and a Cancer , ...
Cached Biology Technology:Structural Analysis of Glycosylated Peptides in Complex Mixtures with , Ion Trap MSn 2Structural Analysis of Glycosylated Peptides in Complex Mixtures with , Ion Trap MSn 3Structural Analysis of Glycosylated Peptides in Complex Mixtures with , Ion Trap MSn 4Structural Analysis of Glycosylated Peptides in Complex Mixtures with , Ion Trap MSn 5Structural Analysis of Glycosylated Peptides in Complex Mixtures with , Ion Trap MSn 6Identification of Low-Level Oxidation Products in Calmodulin Using NanoSpray , Ion Trap Mass Spectrometry 2Identification of Low-Level Oxidation Products in Calmodulin Using NanoSpray , Ion Trap Mass Spectrometry 3Identification of Low-Level Oxidation Products in Calmodulin Using NanoSpray , Ion Trap Mass Spectrometry 4Identification of Low-Level Oxidation Products in Calmodulin Using NanoSpray , Ion Trap Mass Spectrometry 5Identification of Low-Level Oxidation Products in Calmodulin Using NanoSpray , Ion Trap Mass Spectrometry 6RNAi Gene Silencing System 2RNAi Gene Silencing System 3
(Date:4/17/2014)... study suggests that fish consumption advisories for expecting ... long-lived contaminants like persistent organic pollutants (POPs). ... researchers including University of Toronto Scarborough PhD student ... how different levels of environmental contamination, a mother,s ... in the body influenced exposure in her children. ...
(Date:4/17/2014)... hundred births, Down syndrome - or trisomy 21 - ... It results from a chromosomal abnormality where cells of ... (1% of the human genome). A study conducted by ... Genetic Medicine and Development at the University of Geneva ... shed light on how the extra chromosome 21 upsets ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3
... The apparently random self-assembly of molecular threads into the ... frantic than previously thought, Michigan State University scientists say. ... the nature of some diseases. How proteins spontaneously ... wide variety of functional or malfunctioning three-dimensional ...
... A phylogenetic analysis can take a long time to ... efficiently and effectively. The National Institute for Mathematical and ... focusing on high performance computing (HPC) for phylogenetics. ... to use TeraGrid, the CIPRES Portal, the iPlant Discovery ...
... The American Physical Society (APS) announces a new public ... public libraries in the United States full use of ... back to the first issue in 1893, a collection ... provide this access at no cost to participating public ...
Cached Biology News:Scientists post lower speed limit for cell-signaling protein assembly 2
Hybridization chamblers suitable for use with all ChIP-GLAS microarrays....
Rabbit polyclonal to BCA1 ( Abpromise for all tested applications). Antigen: Generated using E.coli expressed mouse BCA1. Entrez GeneID: 10563 SWISS Protein ID: O43927...
SH3 Proteins II Sampler Kit 10g each...
Tumor Suppressor Sampler Kit 10 mu g each...
Biology Products: